@article{392f17908eba41daa99b01111d378c0e,
title = "Protocol and statistical analysis plan for the mega randomised registry trial research program comparing conservative versus liberal oxygenation targets in adults receiving unplanned invasive mechanical ventilation in the ICU (Mega-ROX)",
abstract = "Background: The effect of conservative versus liberal oxygen therapy on 90-day in-hospital mortality in patients who require unplanned invasive mechanical ventilation in an intensive care unit (ICU) is uncertain and will be evaluated in the mega randomised registry trial research program (Mega-ROX). Objective: To summarise the protocol and statistical analysis plan for Mega-ROX. Design, setting and participants: Mega-ROX is a 40 000-patient parallel-group, registry-embedded clinical trial in which adults who require unplanned invasive mechanical ventilation in an ICU will be randomly assigned to conservative or liberal oxygen therapy. Within this overarching trial research program, three nested parallel randomised controlled trials will be conducted. These will include patients with suspected hypoxic ischaemic encephalopathy (HIE) following resuscitation from a cardiac arrest, patients with sepsis, and patients with non-HIE acute brain injuries or conditions. Main outcome measures: The primary outcome is in-hospital all-cause mortality up to 90 days from the date of randomisation. Secondary outcomes include duration of survival, duration of mechanical ventilation, ICU length of stay, hospital length of stay, and proportion of patients discharged home. Results and conclusions: Mega-ROX will compare the effect of conservative versus liberal oxygen therapy on 90-day in-hospital mortality in critically ill adults who receive unplanned invasive mechanical ventilation in an ICU. The protocol and a pre-specified approach to analyses are reported here to mitigate analysis bias. Trial registration: Australian and New Zealand Clinical Trials Registry (ANZCTRN 12620000391976).",
author = "Young, {Paul J.} and Arabi, {Yaseen M.} and Bagshaw, {Sean M.} and Rinaldo Bellomo and Tomoko Fujii and Rashan Haniffa and Hodgson, {Carol L.} and Vijayaraghavan, {Bharath Kumar Tirupakuzhi} and Edward Litton and Diane Mackle and Nichol, {Alistair D.} and Jessica Kasza",
note = "Funding Information: Mega-ROX is funded by grants from the Health Research Council of New Zealand and by an unrestricted donation from the Alpha Charitable Trust. The Low Oxygen Intervention for Cardiac Arrest Injury Limitation (LOGICAL) Mega-ROX substudy is funded by the Australian National Health and Medical Research Council. In Canada, Mega-ROX has received funding from the Pragmatic Trials Platform – Alberta Strategy for Patient-Oriented Research (SPOR) Support Unit. The funding bodies have had no input into the design or conduct of the trial or into the statistical analysis plan, and will have no input into analysis or reporting of the results. The study is coordinated in New Zealand by the Medical Research Institute of New Zealand and in Australia by the Australian and New Zealand Intensive Care Research Centre. The study is coordinated in Ireland by the Irish Critical Care Clinical Trials Network, which is supported by the Health Research Board. The study is coordinated in Canada by the University of Alberta. The study is coordinated in Japan by Jikei University. The study is coordinated in Asia by the Critical Care Asia Network and in Africa by the Critical Care Africa Network (parts of the National Intensive Care Surveillance, Mahidol–Oxford Tropical Medicine Research Unit [NICS-MORU] collaboration), which are supported by a Wellcome Innovations grant (215522). This study is endorsed by the Australia and New Zealand Intensive Care Society Clinical Trials Group, the Irish Critical Care Clinical Trials Group, and the Alberta Health Services Critical Care Strategic Clinical Network. Funding Information: Acknowledgements: Mega-ROX is funded by grants from the Health Research Council of New Zealand and by an unrestricted donation from the Alpha Charitable Trust. The Low Oxygen Intervention for Cardiac Arrest Injury Limitation (LOGICAL) Mega-ROX substudy is funded by the Australian National Health and Medical Research Council. In Canada, Mega-ROX has received funding from the Pragmatic Trials Platform – Alberta Strategy for Patient-Oriented Research (SPOR) Support Unit. The funding bodies have had no input into the design or conduct of the trial or into the statistical analysis plan, and will have no input into analysis or reporting of the results. The study is coordinated in New Zealand by the Medical Research Institute of New Zealand and in Australia by the Australian and New Zealand Intensive Care Research Centre. The study is coordinated in Ireland by the Irish Critical Care Clinical Trials Network, which is supported by the Health Research Board. The study is coordinated in Canada by the University of Alberta. The study is coordinated in Japan by Jikei University. The study is coordinated in Asia by the Critical Care Asia Network and in Africa by the Critical Care Africa Network (parts of the National Intensive Care Surveillance, Mahidol–Oxford Tropical Medicine Research Unit [NICS-MORU] collaboration), which are supported by a Wellcome Innovations grant (215522). This study is endorsed by the Australia and New Zealand Intensive Care Society Clinical Trials Group, the Irish Critical Care Clinical Trials Group, and the Alberta Health Services Critical Care Strategic Clinical Network. Publisher Copyright: {\textcopyright} 2022, College of Intensive Care Medicine. All rights reserved.",
year = "2022",
month = jun,
day = "6",
doi = "10.51893/2022.2.OA4",
language = "English",
volume = "24",
pages = "137--149",
journal = "Critical Care and Resuscitation",
issn = "1441-2772",
publisher = "Australasian Medical Publishing Co. Pty Ltd. (AMPCo)",
number = "2",
}